Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
One Percent Rule Checklist For Safer Forex Trading Risk 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
BOSTON, April 24, 2017 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday, May 1, 2017 at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended March 31, 2017.
The call can be accessed by dialing 1-844-309-0618 (U.S. and Canada) or 1-661-378-9465 (international). The passcode for the conference call is 8375689. To access the slides and live webcast or the subsequent archived recording, visit the “Investors & Media” section of the ZIOPHARM website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company’s website for two weeks.
About ZIOPHARM Oncology, Inc.:
ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing, which are focused on hematologic and solid tumor malignancies.
Contact: Amy Trevvett Vice President, Corporate Communications and Investor Relations 617-502-1881 [email protected] David Pitts Argot Partners 212-600-1902 [email protected]
